WP
ABBV icon

Waycross Partners’s AbbVie ABBV Stock Holding History

Waycross Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.1M Sell
165,943
-16,533
-9% -$3.67M 3.45% 10
2025
Q4 		$41.7M Buy
182,476
+5,063
+3% +$1.15M 3.41% 10
2025
Q3 		$41.1M Buy
177,413
+8,077
+5% +$1.64M 3.53% 11
2025
Q2 		$31.4M Buy
169,336
+12,050
+8% +$2.24M 2.96% 13
2025
Q1 		$33M Buy
157,286
+22,282
+17% +$4.33M 3.69% 8
2024
Q4 		$24M Buy
135,004
+4,019
+3% +$739K 3.11% 8
2024
Q3 		$25.9M Buy
130,985
+2,718
+2% +$507K 3.58% 7
2024
Q2 		$22M Buy
128,267
+12,086
+10% +$2M 3.38% 8
2024
Q1 		$21.2M Buy
116,181
+6,534
+6% +$1.13M 3.64% 7
2023
Q4 		$17M Sell
109,647
-5,102
-4% -$744K 3.19% 9
2023
Q3 		$17.1M Buy
114,749
+4,653
+4% +$683K 3.78% 6
2023
Q2 		$14.8M Buy
110,096
+18,433
+20% +$2.7M 3.22% 7
2023
Q1 		$14.6M Buy
91,663
+17,067
+23% +$2.61M 4.24% 3
2022
Q4 		$12.1M Buy
74,596
+34,641
+87% +$5.31M 4.37% 3
2022
Q3 		$5.36M Sell
39,955
-285
-0.7% -$40.9K 3.61% 4
2022
Q2 		$6.16M Buy
40,240
+2,348
+6% +$359K 4.09% 3
2022
Q1 		$6.14M Buy
37,892
+3,454
+10% +$502K 3.58% 3
2021
Q4 		$4.66M Buy
34,438
+5,200
+18% +$614K 2.67% 5
2021
Q3 		$3.15M Sell
29,238
-27,362
-48% -$3.13M 1.98% 14
2021
Q2 		$6.38M Buy
56,600
+27,611
+95% +$3.11M 3.39% 6
2021
Q1 		$3.14M Buy
28,989
+12,000
+71% +$1.28M 1.75% 18
2020
Q4 		$1.82M Buy
+16,989
New +$1.63M 1.13% 29

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Waycross Partners's ABBV Position: Q1 2026 in Review

Waycross Partners reduced its AbbVie (ABBV) stake by 9.1% in Q1 2026, selling an estimated $3.67M and leaving 165,943 shares worth $36.1M. The position accounts for 3.45% of the portfolio, ranked #10.

Waycross Partners first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $41.7M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Waycross Partners held 165,943 shares of AbbVie worth $36.1M as of Q1 2026.
  • Waycross Partners sold 16,533 AbbVie shares in Q1 2026, an estimated $3.67M.
  • AbbVie made up 3.45% of Waycross Partners's portfolio in Q1 2026, its #10 holding.
  • Waycross Partners first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • Waycross Partners's AbbVie position peaked at $41.7M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Waycross Partners's 13F filing for Q1 2026, filed 7 May 2026.